Literature DB >> 23812014

Controversy in urinary tract infection management in children: a review of new data and subsequent changes in guidelines.

Jameela Abdulaziz Kari1, Kjell Tullus.   

Abstract

Controversy and lack of consensus have been encountered in the management of pediatric urinary tract infection (UTI), including its diagnosis, radiological investigations and the use of antibiotic therapy. In this review, we discuss the need for radiological investigations and the extent of their use as well as the need for prophylactic antibiotics in children with UTI and vesicoureteral reflux. Only a small proportion of children with first UTI and no history of antenatal renal abnormalities have clinically important malformations. Renal ultrasound should be performed in febrile infants and young children with UTI; a micturating cystourethrogram should not be performed routinely after the first febrile UTI. Long-term antibiotics appear to reduce the risk of recurrent symptomatic UTI in susceptible children, although the clinical benefit is marginal. Current recommendations encourage performing radiological investigations only in children at risk and discourage routine prophylactic antibiotic use.

Entities:  

Keywords:  children; radiological investigations; urinary tract infection; vesicoureteral reflux

Mesh:

Substances:

Year:  2013        PMID: 23812014     DOI: 10.1093/tropej/fmt054

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  2 in total

1.  Urinary tract infection in children younger than 5 years. Etiology and associated urological anomalies.

Authors:  Wallaa A Garout; Hassan S Kurdi; Abdulrahman H Shilli; Jameela A Kari
Journal:  Saudi Med J       Date:  2015-04       Impact factor: 1.484

2.  Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism and Vesicoureteral Reflux in Children: A Meta-Analysis of 14 Case-Control Studies.

Authors:  Jin-Wei Ai; Yu Liu; Xian-Tao Zeng; Qing Lei; Li Zou; Bin Pei
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.